M&A Deal Summary |
|
|---|---|
| Date | 2016-03-28 |
| Target | Vixen Pharmaceuticals |
| Sector | Life Science |
| Buyer(s) | Aclaris |
| Deal Type | Add-on Acquisition |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 2012 |
| Sector | Life Science |
| Employees | 57 |
| Revenue | 31M USD (2023) |
Aclaris is a clinical stage specialty pharmaceutical company focused on identifying, developing and commercializing innovative and differentiated drugs to address significant unmet needs in dermatology. Aclaris was founded in 2012 and is based in Wayne, Pennsylvania.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Life Science) | 1 of 2 |
| Type (Add-on Acquisition) | 1 of 2 |
| Country (United States) | 1 of 2 |
| Year (2016) | 1 of 1 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2017-08-08 |
Confluence Life Sciences
Saint Louis, Missouri, United States Confluence Life Sciences, Inc. is a privately held biotechnology company focused on the discovery and development of kinase inhibitors to treat inflammatory and immunological disorders and cancer. Confluence Life Sciences was founded in 2010 and is based in Saint Louis, Missouri. |
Buy | $10M |
